Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Exact Sciences Corp (NASDAQ: EXAS) closed at $53.32 in the last session, down -3.60% from day before closing price of $55.31. In other words, the price has decreased by -$3.60 from its previous closing price. On the day, 3.89 million shares were traded. EXAS stock price reached its highest trading level at $55.46 during the session, while it also had its lowest trading level at $52.195.
Ratios:
We take a closer look at EXAS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 51.81. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.73. In the meantime, Its Debt-to-Equity ratio is 1.06 whereas as Long-Term Debt/Eq ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On March 13, 2025, RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.Barclays initiated its Overweight rating on January 23, 2025, with a $70 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when Zanotti Katherine S sold 3,207 shares for $53.20 per share. The transaction valued at 170,612 led to the insider holds 72,759 shares of the business.
Zanotti Katherine S bought 3,207 shares of EXAS for $170,612 on Jun 13 ’25. On Nov 13 ’24, another insider, Conroy Kevin T, who serves as the President and CEO of the company, bought 19,500 shares for $51.35 each. As a result, the insider paid 1,001,325 and bolstered with 1,074,191 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 10058178560 and an Enterprise Value of 11777115136. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.56 while its Price-to-Book (P/B) ratio in mrq is 4.20. Its current Enterprise Value per Revenue stands at 4.164 whereas that against EBITDA is 309.176.
Stock Price History:
The Beta on a monthly basis for EXAS is 0.94, which has changed by 0.15012944 over the last 52 weeks, in comparison to a change of 0.11844492 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $72.83, while it has fallen to a 52-week low of $39.97. The 50-Day Moving Average of the stock is -1.03%, while the 200-Day Moving Average is calculated to be -3.28%.
Shares Statistics:
According to the various share statistics, EXAS traded on average about 2.94M shares per day over the past 3-months and 3193410 shares per day over the past 10 days. A total of 188.59M shares are outstanding, with a floating share count of 185.74M. Insiders hold about 1.53% of the company’s shares, while institutions hold 97.51% stake in the company. Shares short for EXAS as of 1749772800 were 7931112 with a Short Ratio of 2.70, compared to 1747267200 on 11138144. Therefore, it implies a Short% of Shares Outstanding of 7931112 and a Short% of Float of 4.81.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.14, with high estimates of $0.18 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.32 and $0.09 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $1.0, with 9.0 analysts recommending between $1.6 and $0.74.
Revenue Estimates
According to 24 analysts, the current quarter’s revenue is expected to be $774.35M. It ranges from a high estimate of $794M to a low estimate of $768.9M. As of the current estimate, Exact Sciences Corp’s year-ago sales were $699.26MFor the next quarter, 24 analysts are estimating revenue of $796.69M. There is a high estimate of $808M for the next quarter, whereas the lowest estimate is $787M.
A total of 23 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $3.11B, while the lowest revenue estimate was $3.06B, resulting in an average revenue estimate of $3.1B. In the same quarter a year ago, actual revenue was $2.76BBased on 26 analysts’ estimates, the company’s revenue will be $3.49B in the next fiscal year. The high estimate is $3.6B and the low estimate is $3.41B.
